HUTCHMED (China) Limited Sponsored ADR (HCM) – What Are Investment Firms Thinking About This Stock?

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $14.87.

HCM has been the topic of several research analyst reports. Bank of America cut their price objective on HUTCHMED from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. HSBC upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research note on Tuesday, September 8th. Wall Street Zen raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings lowered shares of HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Finally, The Goldman Sachs Group reduced their target price on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday, July 23rd.

HUTCHMED Trading Up 0.9%

NASDAQ HCM opened at $14.18 on Tuesday. HUTCHMED has a 52 week low of $9.77 and a 52 week high of $16.33. The business has a 50 day moving average price of $13.40 and a 200-day moving average price of $12.63. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64.

HUTCHMED (NASDAQ:HCM) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09). The business had revenue of $139.14 million for the quarter, compared to analysts’ expectations of $304.16 million. On average, analysts predict that HUTCHMED will post 0.23 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Amundi lifted its position in shares of HUTCHMED by 4.0% during the first quarter. Amundi now owns 232,246 shares of the company’s stock worth $3,474,000 after acquiring an additional 8,916 shares in the last quarter. XY Capital Ltd boosted its holdings in shares of HUTCHMED by 115.2% in the second quarter. XY Capital Ltd now owns 104,130 shares of the company’s stock worth $1,120,000 after acquiring an additional 55,736 shares during the period. Finally, Janney Montgomery Scott LLC bought a new position in shares of HUTCHMED in the first quarter worth $365,000. 8.82% of the stock is owned by institutional investors.

HUTCHMED Company Profile

HUTCHMED (NASDAQ:HCM) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and immunological diseases. Founded in 2000, the company has built an integrated research and development platform spanning drug discovery, clinical development, regulatory activities and commercialization.

HUTCHMED’s portfolio includes targeted therapies and other treatments for solid tumors and hematologic malignancies. Its medicines include fruquintinib, marketed in China as Elunate and in the United States as Fruzaqla, and savolitinib, marketed in China as Orpathys through a collaboration with AstraZeneca.